Business Wire

CIVITAS-INVESTMENT

18.6.2020 08:02:13 CEST | Business Wire | Press release

Share
Civitas Investment Management Limited: Leading UK Social Impact Investment Manager Launches with AUM of £2 billion

From today all the investment management activities of the Civitas Group have been brought together under the new name of Civitas Investment Management Limited (“CIM” or “the Group”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005883/en/

CIM is a leading impact investor specialising in government-backed real assets that produce beneficial and sustainable social outcomes. Today, CIM announces expanded client mandates with combined assets under management (“AUM”) of £2 billion.

In all of CIM’s investment activities the Group aims to achieve measurable social impact at scale whilst delivering consistent long-term return profiles for investors together with value for money for the public purse. This is reflected in better personal outcomes and an enhanced quality of life for people living in the Group’s properties.

CIM’s performance in achieving these aims is monitored by independent social impact consultants who challenge and assist CIM in its investment frameworks.

Having established a leading presence in the UK for care-based housing and healthcare CIM is now expanding further into community based infrastructure and is planning to launch in the EU during the next 12 months.

New Website

To support these plans CIM has launched a new dedicated website that outlines its activities, social objectives and profiles the range of investment strategies that are delivered for institutional investors around the world (www.civitasim.com ).

Who We Are

CIM is a pioneer in introducing ethical, long-term private capital into the affordable housing and healthcare sectors, initially in England and Wales, then more widely in the UK and now with plans to access major EU countries.

In 2016 CIM launched Civitas Social Housing PLC, (“CSH”) as the first premium London listed real estate investment trust dedicated to investing in care-based housing for working age adults with long-term healthcare needs.

CSH is now a FTSE 250 company and the leading provider of care-based community housing in the UK with a portfolio of more than 600 buildings independently valued at nearly £900 million. Located across 164 local authority areas, supported by 117 specialist care providers, and 15 housing partners CSH provides bespoke, high quality adapted homes for over 4,200 people.

Reflecting the success of the strategy shareholders recently approved an extension of the CSH investment policy to enable the fund to work directly with the NHS, with other leading care providers and with major charities to provide accommodation and other social properties, in short supply within healthcare real estate.

CIM Investment Strategies

Having commenced investing in care-based social housing, CIM has now evolved a range of four broad and complementary investment strategies as follows:

  • Healthcare
  • Social and Affordable Housing
  • Social Infrastructure
  • Urban Regeneration

Across each of the four investment strategies are common themes and investment objectives that include:

  • 100% governmental income and support
  • Value for money for the public purse
  • Stable long-term cash generation
  • Low volatility and low correlation to economic cycles
  • Measurable social and ESG impact

Exclusive Partnerships

To assist in the delivery of the Group’s investment strategies CIM is pleased to have established exclusive partnerships with a number of leading investment houses and global real estate and infrastructure investors with whom CIM shares common ambitions and objectives.

Today CIM’s partners include:

  • Schroders, the global investment manager responsible for more than £500 billion of client assets across multiple investment strategies. CIM and Schroders are exclusive partners delivering new care-based housing, initially for approximately 2,000 people;
  • A leading Asia based global infrastructure and real estate investor has established an exclusive partnership with CIM to invest in housing based social infrastructure assets

Our Vision

The team of professionals working at CIM comes from a range of different backgrounds each offering expertise and operational experience in healthcare, social housing, real estate, social infrastructure and investment management.

They share a common conviction that responsible private capital can play a transformational role in the delivery of social assets that are themselves designed to enhance lives and communities. By investing for the long-term, with measurable social impact a fundamental requirement, the conditions are created for achieving sustainable and ethical returns for investors.

Andrew Dawber, Group Director at Civitas Investment Management Limited commented:

“We are delighted that CIM has reached an important investment milestone based on a growing number of client mandates. We are greatly encouraged by the opportunities in the near term future as we grow and build out our investment funds, deploying capital in projects in the UK, and in Europe in due course. We are experiencing strong and growing demand from portfolio managers who increasingly recognise the attractions of investing in the asset classes that CIM promotes.

We are especially proud of the team that we have built at CIM who each provide different perspectives towards the same goal, creating sustainable investment returns for the long term in projects that deliver genuine social good at a local level wherever that investment is made.”

-ENDS-

Notes to Editors:

Civitas Investment Management Limited (‘CIM’) is a leading impact investment manager that is dedicated to achieving long-term sustainable returns for the Group’s global investors by acquiring community-based assets that deliver positive social outcomes. CIM’s investments are supported by national governments and local municipalities that are themselves seeking to bring about positive societal change. CIM has an AUM of approximately £2 billion with a target to increase to £4 billion over the next two to three years following the build out of client mandates.

Among other impact investment ventures, CIM is the investment adviser to the London listed Civitas Social Housing PLC (“CSH”), the first dedicated London listed REIT to raise long-term sustainable, institutional capital to invest in care-based social homes and healthcare facilities across the UK. So far CIM has on behalf of CSH completed more than 120 individual transactions to build the largest portfolio of its kind in the UK that has been independently valued at approximately £900 million (www.civitassocialhousing.com ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release

Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the

Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release

Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic

Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release

The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled

Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release

India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye